Realizing significant achievements in our research and development efforts
HONG KONG, Dec. 21, 2011 /PRNewswire-Asia/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460) ("Sihuan Pharmaceutical" or the "Company"), a leading pharmaceutical company and the largest cardio-cerebral vascular drug franchise in China by market share, announced that the Apapenem Carbapenems anti-infective drug, developed by the Company's indirectly-owned subsidiary, KBP BioSciences Co., Ltd. ("KBP BioSciences"), has been approved for clinical trial by the State Food and Drug Administration ("SFDA"). Ownership of this product has been successfully transferred to a third party, bringing satisfactory returns on investment for the Group.
Carbapenems is a class-one beta-lactam antibiotic with the widest antibacterial spectrum and the strongest antibiotic activity. More importantly, the tendency of developing resistance to the drug is remarkably low. With its high level of resistance to penicillin, cephalosporin, fluoroquinolone and aminoglycoside antibiotics, Carbapenems is becoming increasingly important in the treatment of various bacterial infections. Since KBP BioSciences started development of Apapenem four years ago, it is expected to be a breakthrough product with high market potential due to its stability, antibacterial qualities and drug metabolism.
Dr. Che Fengsheng, Chairman and CEO of the Company, said, "We believe that the approval of clinical trial for Apapenem is a breakthrough in our research and development efforts. So far, very few domestic pharmaceutical companies have been able to achieve this milestone, which reflects our enhanced and industry-leading capabilities in research and development, particularly in developing innovative drugs. At present, we have 10 innovative patented drugs at various stages of development. We have also received approval from the SFDA for clinical trial for one drug and have four cases pending approval, and have one CCV drug at the clinical research stage. Looking ahead, we will continue to be active in promoting the development of innovative drugs while continuing to demonstrate our strong capabilities in the research and development of generic drugs, providing impetus for the sustained growth of the Company."
About Sihuan Pharmaceutical Holdings Group Ltd.
Founded in 2001, Sihuan Pharmaceutical Holdings Group Ltd. is a leading pharmaceutical company and the largest cardio-cerebral vascular drug franchise in China by market share. The success of the Group can be attributed to its differentiated and proven sales and marketing model, diversified portfolio of market leading drugs, extensive nationwide distribution network and strong research and development capabilities. The sales network covers nearly 10,000 hospitals through over 2,000 distributors in all 31 provinces, autonomous regions and cities throughout China. The company currently sells 87 products encompassing the top five medical therapeutic areas in China: cardiovascular system, anti-infective, metabolism, oncology and nervous system. Their major products such as Kelinao, Anjieli, Chuanqing, Qu'Ao and Aogan are widely used in the treatment of various cardio-cerebral vascular diseases.
